Alivia Kaylor on Muck Rack

Alivia Kaylor

Columbus
As seen in: Pharma News Intelligence, PharmaLifeScience, Yahoo Finance, TechTarget, TechTarget Health IT and EHR, Healthcare Dive, HealthIT Analytics, PharmaVOICE, Cyber Era
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alivia

Contact Alivia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Don't miss the most important voices in pharma Original

|
By Alivia Kaylor
| PharmaVOICE
This audio is auto-generated. Please let us know if you have feedback. Years after the onset of the pandemic, the massive financial windfall that came from Pfizer's COVID-19 vaccine and antiviral therapy has largely dried up, while pipeline setbacks have complicated the company's path forward. The drugmaker is now at a critical inflection point.
Open in Who Shared View Duplicates (2) Issue with article?

Structure's GLP-1 obesity pill could compete with others on the market

|
By Alivia Kaylor
| TechTarget
Structure Therapeutics reported positive top-line results from a phase 2 trial of its GLP-1 pill, aleniglipron, at the American Diabetes Association meeting in New Orleans. The drug, which has been touted as a potential competitor to Novo Nordisk's Wegovy and Eli Lilly's Foundayo pills, spurred up to 15.3% weight loss at 36 weeks with no signs of plateauing.
Open in Who Shared Issue with article?

CVS brings back Lilly's Zepbound coverage, adds obesity pill Foundayo

|
By Alivia Kaylor
| TechTarget
CVS Health said yesterday it will restore coverage of Eli Lilly's blockbuster weight loss shot Zepbound and add the pharma giant's recently approved obesity pill, Foundayo, to Caremark's standard formulary. The move follows a pricing deal Novo reached last year with CVS, which made Wegovy the preferred obesity therapy on standard plans, cutting coverage for Zepbound in July.
Open in Who Shared Issue with article?
See all 239 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Alivia

Contact Alivia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified